Letrozole cas  to Treat Urinary Tract Infections And Gonorrhea  (jerryzhang001@chembj.com) - Nanjing Bangnuo Biotechnology Co., Ltd.

Letrozole cas  to Treat Urinary Tract Infections And Gonorrhea  (jerryzhang001@chembj.com)

Product Description

Letrozole CAS  to treat urinary tract infections and gonorrhea



  1. Description

Letrozole is a new generation of selective aromatase inhibitors. It is a synthetic benzyl triazole derivative, can inhibit aromatase and decrease estrogen levels, further eliminates the stimulation of estrogen on tumor growth. The activity of letrozole in the body is 150-250 times more than that of the first generation of aromatase inhibitors - aminoglutethimide. 

 Preclinical studies have shown that Letrozole is of no potential toxicity to each system and target organ in the body, no mutagenic and carcinogenic effect, little side reaction, well tolerated, and compared with other aromatase inhibitors and anti-estrogen drugs, it has a stronger antitumor effect. Applicable to the treatment of advanced breast cancer in postmenopausal patients who anti-estrogen ineffective, and early breast cancer.

In December 2005, the British drug and health care products regulatory approved letrozole (furlong) produced by Swiss Novartis used to treat breast cancer patients, and allowed it to treat early invasive breast cancer patients after the surgery caused by positive postmenopausal hormone

Other products

Company Info

Nanjing Bangnuo Biotechnology Co., Ltd.
Contact Person:
Jerry Zhang